Prostate Cancer - Results from #120

Lutetium-177-prostate-specific membrane antigen therapy for prostate cancer: current status and future prospects. December 5, 2024

In-field prostate cancer recurrence following radical prostatectomy and salvage radiation. December 5, 2024

Testing BRCA 1-2 Mutations in Metastatic Prostate Cancer: Results of a Survey of the Italian Association of Medical Oncology. December 5, 2024

Transperineal 3D fusion imaging-guided targeted microwaves ablation for low to intermediate-risk prostate cancer: results of a phase I-II study. December 5, 2024

Impact of androgen deprivation therapy in patients with unfavorable intermediate-risk prostate cancer receiving brachytherapy-based dose-escalated radiation therapy. December 5, 2024

Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial December 4, 2024

Landmark HIFI Study Publication Demonstrates Positive Outcomes with Focal One® Robotic HIFU Versus Surgery in the Management of Prostate Cancer December 4, 2024

First 2 Participants Dosed with Cu-64 SAR-bisPSMA in Co-PSMA Trial December 4, 2024

Safety of PSMA radioligand therapy in mCRPC patients with preexisting moderate to severe thrombocytopenia. December 4, 2024

Intratumoral heterogeneity drives acquired therapy resistance in a patient with metastatic prostate cancer. December 4, 2024

Surgical and oncological outcomes of salvage radical prostatectomy after focal therapies: a matched-pair analysis. December 4, 2024

Evaluating the Prognostic Impact of Apparent Diffusion Coefficient in Definitive Radiotherapy for Gleason Score 7 Prostate Cancer Patients. December 4, 2024

Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024. December 4, 2024

Prostate cancer in people with HIV. December 4, 2024

Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review. December 4, 2024

Cell-autonomous IL6ST activation suppresses prostate cancer development via STAT3/ARF/p53-driven senescence and confers an immune-active tumor microenvironment. December 3, 2024

ASCL1 regulates and cooperates with FOXA2 to drive terminal neuroendocrine phenotype in prostate cancer. December 3, 2024

Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with 213Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors. December 3, 2024

Preoperative Briganti Nomogram Score and Risk of Prostate Cancer Progression After Robotic Surgery Beyond EAU Risk Categories. December 3, 2024

Adipose Tissues Have Been Overlooked as Players in Prostate Cancer Progression. December 3, 2024

Page 7 of 1449